For the purposes of this Code, the terms listed below are understood to have the following definitions:
Recipient: Any Healthcare Professional or Healthcare Organisation as applicable, in each case, whose primary practice, principal professional address or place of incorporation is in Spain.
Donations and Grants: An act of generosity through which a company (donor) makes an amount of money, goods or services (donation in kind) freely available to a third party (donee), which accepts it. At times, grants (finalist donations) is the name for those cases in which the money, goods or services are intended for the fulfillment of a given objective, the execution of a project or the completion of an activity by the donee. In all cases, the donor will not receive or request any compensation from the donee (regulated by article 15 of the Code).
Interaction: Activities performed, organised or sponsored by a pharmaceutical company, or under its control — subsidiaries, foundations, associations, institutes, agencies, third-party providers, etc. — from which direct or indirect collaboration, support and/or compensation of any kind may be derived by a third party.
Research and Development: Activities related to the planning or conduct of (i) non-clinical studies (as defined by the OECD "Principles of Good Laboratory Practices"), (ii) clinical trials (as defined by Regulation (EU) no. 536/2014 of the European Parliament and of the Council, by Royal Decree 1090/2015 and considered in article 14.1 of the Code) and (iii) observational studies with medicinal products studies (considered in article 14.2 of the Code).
Medicinal Product for Human Use: Any substance or combination of substances that is presented as having properties for the treatment or prevention of disease in humans, or that may be used in humans or administered to humans for the purpose of restoring, correcting or modifying physiological functions by exercising pharmaceutical, immunological or metabolic action, or for the purpose of establishing a medical diagnosis.3
Any mention in this Code to medicines is understood to refer to a medicinal product for human use.
Patient Organisation: A non-profit organisation ― including umbrella organisations to which they belong — composed primarily of patients and/or their caregivers that represents and/or supports the needs of patients and/or their caregivers.
Healthcare Organisation: Any legal body or entity (i) that is a medical or scientific organisation, healthcare institution (of any legal status or organisation), such as hospitals, clinics, foundations, universities and other academic entities, scientific societies (excluding Patient Organisations covered by article 17 of this Code), or (ii) through which one or more Healthcare Professionals provide services.
Market Price: The amount a private party should generally have to pay in order to acquire a unit of a good, product, material, article or similar in Spain.
Healthcare Professionals: Any member of the medical, dental, pharmaceutical, nursing or podiatric profession, any other person legally considered as such, or any other person who, in exercising their profession, may perform or participate directly or indirectly in the prescription, purchase, supply, dispensation or administration of medicinal products for human use.
For the purpose of this Code veterinarian professionals are excluded from this concept.
Promotion: Any activity performed, organised or sponsored by a pharmaceutical company, or under its control — subsidiaries, foundations, associations, institutes, agencies, etc. — designed to favour, either directly or indirectly, the prescription, dispensation, recommendation, sale or consumption of medicinal products for human use.
Social Media: Social media channels allow for two-way communication based on the Internet, thanks to which individual users or groups can share information, knowledge and opinions. Their key characteristic is, indeed, conversational character generated between the issuer and the receiver of a message, turning all participants in the conversation into issuers and receivers. Social media fosters interaction, in most cases in real time, making it a fully effective media channel.
Scientific-professional Meetings: Any meeting, seminar, congress, conference, symposium, in-person or distance educational courses, or any other type of similar activity (including but not limited to expert meetings, visits to manufacturing and research facilities, as well as training meetings for investigators conducting clinical trials and observational studies with medicinal products) organised or sponsored by one or more pharmaceutical companies or under their control. (hereinafter, "Meeting(s)").
Transfers of Value: Any direct or indirect Transfers of Value, whether in cash, in kind or otherwise, regardless of its purpose. Direct: Transfers of Value are those made directly by a pharmaceutical company for the benefit of a Recipient. Indirect: Transfers of value are those made by a third party (provider, agent, partner or affiliate – including foundations -) acting on behalf of a company for the benefit of a Recipient when the company knows or can identify such Recipient.
Transfers of Value made as part of commercial transactions between pharmaceutical companies and distributors, pharmacy offices and Healthcare Organisations are excluded from this concept.
3 Article 2 of the Royal Legislative Decree 1/2015, of 24 July, approving consolidated Law 29/2006 on Guarantees and Rational Use of Medicinal Products and Medical Devices.